The Phase 2 data (14.8% weight loss at 13 weeks with reported muscle preservation) are remarkable if confirmed, suggesting rapid, substantial weight loss that approaches semaglutide's 68-week results in just a fraction of the time
Renal impairment GLP-1 RAs are generally safe in patients with CKD and have demonstrated nephroprotective effects in the FLOW trial, where semaglutide significantly reduced the composite renal endpoint (hospitalization for acute kidney injury, sustained 50% decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal death) in patients with type 2 diabetes and CKD [15]
You see, dealing with free radicals is like handing off a hot potato
Post-renal: obstruction (stones, enlarged prostate, tumors)
The Influence of Tropicamide on Intraocular Pressure
You can use MeAgain with or instead of Lose It If you already use Lose It, the useful habits transfer naturally: logging meals, watching protein or macros, recording weight, checking patterns, and building consistency
